gutflix
GI learning, personalised

Summary

After the first biologic failure, the next choice matters: Building confidence beyond conventional targets through comprehensive disease control with mirikizumab in UC (Eli Lilly and Company) (Complete Session)

Yamile Zabana

UEG Week Barcelona 2026 Presentation

October 18, 2026

A Lilly-sponsored symposium presented data on mirikizumab, an IL-23 blocker, showing durable efficacy over four years in ulcerative colitis patients across multiple endpoints including bowel urgency, clinical and endoscopic remission, histologic healing, and disease clearance, with no new safety signals observed.

KEY POINTS

- The speaker reported that in the PODCAST real-world study of 10 countries, approximately 48% of UC patients had uncontrolled disease according to STRIDE-II criteria, highlighting the need for comprehensive disease management beyond conventional clinical symptoms.
- The speaker stated that mirikizumab demonstrated improvement in bowel urgency as early as week 2, with approximately 71% of patients achieving symptomatic remission at one year versus 40% on placebo, and nine out of ten patients who achieved symptomatic remission maintained it for up to four years.
- The speaker reported that roughly three out of four patients achieved disease clearance (combined clinical, endoscopic, and histologic remission) at one year, with 50 to 60% maintaining this outcome through years 2 to 4, though bio-experienced patients had numerically lower rates by year four.
- The speaker stated that two-thirds of patients maintained combined histologic and endoscopic mucosal remission over four years in the long-term extension, and 100% of bio-experienced patients who achieved clinical remission at year one maintained it over four years without corticosteroid use.

- The speaker reported very low rates of hospitalization and colectomy in the Lucent studies, with one hospitalization and zero surgeries in the long-term extension, though the speakers acknowledged these trial populations differ from general UC cohorts where colectomy rates have remained stable over 20 years.
- The speaker stated that safety data from the long-term extension showed no new safety signals, with very low rates of serious adverse events including serious and opportunistic infections, and the most common adverse event was COVID reflecting the timing during the pandemic.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/f4c4097e-d14f-11f1-8ff8-daaa6dbee0a2

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.